The potential for antibody-dependent enhancement of SARS-CoV-2 infection: Translational implications for vaccine development

Wang, Jiong; Zand, Martin S.

doi:10.1017/cts.2020.39

Cited by 22 publications

(20 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Binding of these MAbs with virus particles functionally mimics the virus receptor and mediates entry by causing conformational changes that make the spike protein more prone to undergo proteolytic activation (Wan et al, 2020 ). With respect to the current COVID-19 pandemic caused by SARS CoV-2 virus (Mitchell, 2020 ), it is imperative that careful testing and validation of prospective vaccines and MAb-based therapies be done to avoid adverse consequences as a result of coronavirus ADE (Wang and Zand, 2020 ). A summary of the different animal and/or cell models used, and the specific phenotypes studied in different publications is given in Table 1 .…”

Section: Ade In Other Virusesmentioning

confidence: 99%

Intrinsic ADE: The Dark Side of Antibody Dependent Enhancement During Dengue Infection

Narayan

Tripathi

2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Dengue fever is an Aedes mosquito-borne illness caused by any one of the four different dengue virus (DENV) serotypes (1–4) and manifests in the form of symptoms ranging from mild or asymptomatic to severe disease with vascular leakage, leading to shock, and viral hemorrhagic syndrome. Increased risk of severe disease occurs during secondary infection with a virus serotype distinct from that of prior dengue infection. This occurs by antibody dependent enhancement (ADE) of infection, wherein sub-neutralizing antibodies against the virus particles opsonize dengue virus entry via formation of immune complexes that interact with fragment crystallizable gamma receptors (FcγR) on monocytes, dendritic cells, and macrophages. The ADE phenomenon has two components: Extrinsic and Intrinsic ADE. While extrinsic ADE contributes to enhanced virus entry, intrinsic ADE results in heightened virus production by inhibition of type1 interferon and activation of interleukin-10 biosynthesis, thereby favoring a Th2 type immune response. Intrinsic ADE has greater contribution in enhancing Dengue replication as compared to extrinsic ADE. Detailed elucidation of intrinsic ADE during secondary dengue infection can increase our understanding of DENV-pathogenesis and aid in the development of host-targeting antivirals. Here we review literature focusing on intrinsic factors contributing to severe dengue pathology and suggest possible avenues for further research.

show abstract

Section: Ade In Other Virusesmentioning

confidence: 99%

Intrinsic ADE: The Dark Side of Antibody Dependent Enhancement During Dengue Infection

Narayan

Tripathi

2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Vaccine-specific variations in ADE could occur for many reasons, including modifications in vaccine protein glycosylation, vaccine adjuvant, and previous exposure to other CoV strains. Multiplex approaches developed for influenza can be rapidly adapted to this use, particularly to evaluate the balance between vaccine-induced protection from infection against the increased risk of severe disease with the following infection despite vaccination [75] . However, there is not available data that supports ADE contributed by sera in animal models such as vaccinated rats with SARS-CoV-2 RBD and immunized macaques with the SARS-CoV-2 vaccine [76] , [77] .…”

Section: Immune Responsementioning

confidence: 99%

The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies

Molaei

Dadkhah

Asghariazar

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

show abstract

“…However, data on this issue are currently lacking and requires further clarification. 49,50 Another concern with the development of a SARS-CoV-2 vaccine is in ensuring the prevention of disease enhancement. A vaccinated person may develop a more severe condition than a non-vaccinated person upon infection.…”

Section: Sars-cov-2 Vaccine: Efficacy and Safetymentioning

confidence: 99%

Recombinant vaccines for COVID-19

Yadav¹,

Srivastava²,

Mishra³

et al. 2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

SARS-CoV-2, the causative agent of COVID-19, has imposed a major public health threat, which needs effective therapeutics and vaccination strategies. Several potential candidate vaccines being rapidly developed are in clinical evaluation. Considering the crucial role of SARS-CoV-2 spike (S) glycoprotein in virus attachment, entry, and induction of neutralizing antibodies, S protein is being widely used as a target for vaccine development. Based on advances in techniques for vaccine design, inactivated, live-vectored, nucleic acid, and recombinant COVID-19 vaccines are being developed and tested for their efficacy. Phase3 clinical trials are underway or will soon begin for several of these vaccines. Assuming that clinical efficacy is shown for one or more vaccines, safety is a major aspect to be considered before deploying such vaccines to the public. The current review focuses on the recent advances in recombinant COVID-19 vaccine research and development and associated issues.

show abstract

The potential for antibody-dependent enhancement of SARS-CoV-2 infection: Translational implications for vaccine development

Abstract: Cite this article: Wang J and Zand MS. The potential for antibody-dependent enhancement of SARS-CoV-2 infection: Translational implications for vaccine development.

Cited by 22 publications

References 21 publications

Intrinsic ADE: The Dark Side of Antibody Dependent Enhancement During Dengue Infection

Intrinsic ADE: The Dark Side of Antibody Dependent Enhancement During Dengue Infection

The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies

Recombinant vaccines for COVID-19

Contact Info

Product

Resources

About